Repligen Corporation (NASDAQ:RGEN) reported second-quarter revenue that exceeded analyst expectations, driving shares up 5% in pre-market trading as the bioprocessing technology company raised its full-year revenue guidance on strong order momentum.
The company posted revenue of $182 million for the second quarter, surpassing the analyst consensus estimate of $175.35 million and representing a 15% increase compared to the same period last year. Adjusted earnings per share came in at $0.37, slightly below the analyst estimate of $0.39. The company reported 17% organic non-COVID growth, with strength across both consumables and capital equipment segments.
"We had another outstanding quarter in Q2 with 17% organic non-COVID growth. We are very pleased with the momentum we see across the portfolio," said Olivier Loeillot, President and Chief Executive Officer of Repligen. "Orders grew over 20%, which represented the eighth quarter in a row of orders exceeding non-COVID revenue and the fifth quarter of sequential order growth."
The company’s performance was broad-based, with all franchises posting YoY growth. Consumables grew more than 20%, while capital equipment increased in the high-teens. Biopharma revenue grew 20%, and all geographic regions saw mid-teens growth.
Repligen raised its full-year 2025 revenue guidance to a range of $715-735 million, up from the previous consensus of $710.2 million. The company also updated its adjusted earnings per share guidance to $1.65-$1.72, in line with the consensus estimate of $1.68.
The adjusted gross margin for the quarter was 51.1%, unchanged from the same period last year, while the adjusted operating margin was 12.0%, compared to 12.8% in the second quarter of 2024.
Repligen’s cash position remained strong with $709 million in cash, cash equivalents, and short-term investments as of June 30, 2025, compared to $757 million at the end of 2024.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.